Neurontin Off-Label Suit: Plaintiffs’ Experts Claim Pfizer Slanted Studies
Executive Summary
Pharmaceutical companies appear to be facing wider legal pressure to alter the way they create and disseminate studies designed to support marketed products
You may also be interested in...
Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation
Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation
Compendium Listing Not A Shield Against Legal Action For Off-Label Uses
The fact that a drug may be listed for an off-label indication in an approved compendium does not shield the manufacturer from legal action under provisions in the Food, Drug and Cosmetics Act or the False Claims Act, legal experts at a recent Food and Drug Law Institute conference warned
Compendium Listing Not A Shield Against Legal Action For Off-Label Uses
The fact that a drug may be listed for an off-label indication in an approved compendium does not shield the manufacturer from legal action under provisions in the Food, Drug and Cosmetics Act or the False Claims Act, legal experts at a recent Food and Drug Law Institute conference warned